EGFR and neoplasm: Yet, contrary to our expectation in a cell lacking a mutant active ERBB1, we also knew that the ERBB1/2/4 inhibitors lapatinib and afatinib profoundly altered the biology of the ADOR cells as single agents, slowing tumor growth and radically altering the morphology and invasive potential of the cells.